N/A N=181 GORE® EXCLUDER® Endoprosthesis French Mandatory Registry
Abdominal Aortic Aneurysm
Primary: Percentage of Participants Survived at 5 Years — 76 Percentage of participants alive
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Urodynamic Feasibility Study Utilizing the UroLift® System
Benign Prostatic Hyperplasia
Primary: Qmax Assessed Using Urodynamic Testing (Cystometry) — 14.0 mL/sec
N/A N=1,005 Real-World Registry Assessing the Clinical Use of the Lutonix 035 Drug Coated Balloon Catheter
Peripheral Arterial Disease · Peripheral Vascular Diseases · Arterial Occlusive Diseases
Primary: Percentage of Participants With Freedom From Target Lesion Revascularization (TLR) at 12 Months Post Index Procedure — 88.6 percentage of participants
Phase 2 N=68 A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Prostate Cancer
Primary: Lack of Disease Progression at 12 Weeks — 14; 11 Participants
Phase 2 N=30 Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery
Diabetic Retinopathy
Primary: Number of Participants With Ocular and Non-Ocular Adverse Events — 11; 10; 5; 3 Participants
Phase 3 N=229 A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Myelodysplastic Syndromes
Primary: Percentage Of Participants Who Achieved Red Blood Cell Transfusion Independence (RBC-TI) ≥ 8 Weeks From Week 1 to Week 24 — 37.91; 13.16 Percent of Participants…
N/A N=115 TSolution One® Total Knee Arthroplasty
Osteoarthritis, Knee
Primary: Percentage of Patients With Postoperative Coronal Limb Alignment More Than ±3 Deg From the Planned Coronal Limb Alignment — 11.2 percentage of patients
Phase 3 N=62 Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery
Cardiac Complication During Procedure
Primary: Cumulative Transfusion Units — 0; 0 Transfusion Units — p=.908
N/A N=394 Study to Estimate the Burden of Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN) in Italy
Herpes Zoster · Herpes Zoster Vaccine
Primary: Overall Incidence Rate of Herpes Zoster (HZ) Cases, by Age and Gender — 5.19; 6.29; 5.00; 9.19 Number of HZ cases/1000 person-years
N/A N=61 A Feasibility Study to Evaluate the Effect of Concomitant Renal Denervation and Cardiac Ablation on AF Recurrence
Persistent Atrial Fibrillation · Paroxysmal Atrial Fibrillation · Hypertension
Primary: Number of Participants With Freedom From Atrial Fibrillation at 12 Month — 16; 4 Participants — p=0.22
Phase 2 N=266 Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
Glioblastoma
Primary: Adult Study: Overall Survival (OS) — 5.7; 4.6; 4.9; 9.6 months — p== 0.062
Phase 4 N=271 Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
Macular Degeneration
Primary: Change in BCVA as Measured by the ETDRS Letter Score — -2.1; -0.4 Letters correctly read — p=0.0162
Phase 3 N=686 Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
Arthritis, Psoriatic
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 83.7; 16.8 percentage of participants
N/A N=293 Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants
Cholestasis · Cholestasis of Parenteral Nutrition
Primary: Time to Resolution of Parenteral Nutrition Associated Cholestasis Prior to End of Study — 38.02 Days
Phase 2 N=400 Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine
Malaria, Falciparum
Primary: Subjects Time to First Clinical Episode of P Falciparum Malaria During the Efficacy Follow-up Period Adjusted for Time at Risk - Intent to Treat (ITT) Population — 107…